← Back to Search

Local Anesthetic

Trigger Point Injections vs Lidocaine Patch for Myofascial Pain

Phase 4

Recruiting

Led By Jonathan Lee, MD

Research Sponsored by University of California, Irvine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from initiation of the study up to the point the patient is discharged from the emergency department

Awards & highlights

Study Summary

This trial is testing whether trigger point injections of 1% lidocaine are more effective than 5% lidocaine patches at reducing myofascial back and neck pain in the Emergency Department.

Who is the study for?

This trial is for adults with myofascial pain in the neck or back, identified by a specific tender spot that recreates their pain when pressed. It's not for those with spinal tenderness, nerve root pain symptoms (radiculopathy), pregnant individuals, people allergic to lidocaine, those unable to consent, or if there's infection/skin issues at the pain site.Check my eligibility

What is being tested?

The study compares two treatments for easing myofascial back and neck pain in emergency settings: one group receives trigger point injections with 1% lidocaine directly into painful spots; another gets patches containing 5% lidocaine applied on the skin over these areas.See study design

What are the potential side effects?

Possible side effects include discomfort at injection sites for those getting injections and skin irritation where patches are applied. Lidocaine can sometimes cause numbness of the area, tingling sensations, dizziness or an allergic reaction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 0 minutes and 20-minutes post- treatment, and every 30-60 minutes thereafter until discharge or admission and we will give the patient a hand out so that they can record their pain scores for up to 5 days after their emergency department visit.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~0 minutes and 20-minutes post- treatment, and every 30-60 minutes thereafter until discharge or admission and we will give the patient a hand out so that they can record their pain scores for up to 5 days after their emergency department visit.

This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 minutes and 20-minutes post- treatment, and every 30-60 minutes thereafter until discharge or admission and we will give the patient a hand out so that they can record their pain scores for up to 5 days after their emergency department visit. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

absolute change in Numerical Rating Scale (NRS) of pain

Secondary outcome measures

disposition times

satisfaction/experience surveys regarding their treatment

use of other medications for treatment of pain including medications administered

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Trigger point with 1% LidocaineExperimental Treatment1 Intervention

The physician will withdraw 1cc of 1% lidocaine in a 25g needle, sterilely prep the field with a Chloraprep applicator, use index, and middle finger to squeeze the borders of the trigger point and raise the central aspect of the trigger point, insert the needle at 90-degree angle up to 5/8' deep, inject 1cc of the 1% lidocaine after ensuring needle is not in a blood vessel, removing the needle, and then covering the insertion site with a sterile bandage.

Group II: 5% Lidocaine PatchActive Control1 Intervention

5% lidocaine patch will be placed at the point of maximal tenderness upon palpation. Location of placement will be described and instructed by physician and placed by nursing staff.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor

543 Previous Clinical Trials

1,922,891 Total Patients Enrolled

Jonathan Lee, MDPrincipal InvestigatorUCI Department of Emergency Medicine

Media Library

Lidocaine patch 5% (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT05151510 — Phase 4

Myofascial Pain Syndrome Research Study Groups: 5% Lidocaine Patch, Trigger point with 1% Lidocaine

Myofascial Pain Syndrome Clinical Trial 2023: Lidocaine patch 5% Highlights & Side Effects. Trial Name: NCT05151510 — Phase 4

Lidocaine patch 5% (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05151510 — Phase 4

Myofascial Pain Syndrome Patient Testimony for trial: Trial Name: NCT05151510 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have any other experiments been conducted involving Trigger point injection with 1% lidocaine?

"Currently, 118 clinical trials have commenced research into Trigger point injection with 1% lidocaine. Of those active studies, 31 are in the final phase of their trial. 1094 locations across Calgary, Alberta are running these experiments for this form of therapy."

Answered by AI

What is the cap on patient enrollment for this medical experiment?

"Affirmative. Information on clinicaltrials.gov attests to the fact that this research, which was first posted November 1st 2021, is actively searching for enrollees. A total of 110 patients are needed from one medical centre."

Answered by AI

What medical issues is Trigger Point Injection with 1% Lidocaine most commonly employed to address?

"Trigger point injections with 1% lidocaine are generally used to manage cervical syndrome, however they can also prove beneficial for minor burns, transplants, and osteoporosis patients."

Answered by AI

What implications does Trigger point injection with 1% lidocaine have for patients?

"This treatment has already been approved for use, so the safety of trigger point injection with 1% lidocaine is rated a 3 on our scale."

Answered by AI

Are there any available openings for this research endeavor?

"The clinicaltrials.gov platform indicates that this trial is actively recruiting participants, beginning on November 1st 2021 and updated most recently on December 8th 2021."

Answered by AI

Who else is applying?

What state do they live in?

California

What site did they apply to?

Emergency Room at UCI Medical Center

What portion of applicants met pre-screening criteria?

Met criteria

Did not meet criteria

How many prior treatments have patients received?

Why did patients apply to this trial?

pain relief money from study. This year, I discovered that I have Hypermobile Spectrum Disorder and possibly Hypermobile Ehlers-Danlos Syndrome. I have been in and out of physical/occupational therapy for various pains, including neck/upper trap pain that I still have not found a solution for. I hope that this clinical trial will improve my condition.

PatientReceived no prior treatments